Core Insights - Tecan reports mid-single-digit local currency growth in Q3 2025, confirming its full-year 2025 outlook despite previous declines in Q1 and Q2 [1][2][3] Financial Performance - Sales for Q3 2025 increased by a mid-single-digit percentage in local currencies, following a mid-single-digit decline in Q1 and a low-single-digit decline in Q2 [2] - The Life Sciences Business experienced a low-single-digit sales decline, while the Partnering Business achieved a sales increase in the low teens percentage range [2] - Order intake exceeded sales in Q3, maintaining a book-to-bill ratio above 1 [2] Full-Year Outlook - Tecan confirms its full-year sales outlook, expecting sales in local currencies to range from a low single-digit percentage decline to low single-digit percentage growth, with current trends indicating performance will be in the lower half of this range [3] - The adjusted EBITDA margin forecast for full-year 2025 is reiterated at 17.5% to 18.5% of sales [4] Impact of Tariffs and Exchange Rates - The estimated net impact on the adjusted EBITDA margin for 2025 could be around 100 basis points due to higher reciprocal tariff levels [5] - If the current US dollar to Swiss franc exchange rate persists, it may lead to an additional negative impact of approximately 100 basis points on the adjusted EBITDA margin [5] Mid-Term Outlook - Tecan maintains its mid-term outlook, anticipating a return to average organic growth rates in the mid- to high-single-digit percentage range under normal market conditions [6] - Full normalization of end markets is not expected until 2026, with guidance for 2026 to be provided alongside full-year 2025 results [6] Regional Performance - Sales in the US Academia & Government sector are trending toward the middle of the initially assumed range, while demand in China remains subdued [7] - Biopharma sales in the second half of 2025 are expected to align with stable sales development seen in the first half [7] - Newly launched products and growth segments are contributing positively, with sales to the largest Partnering Business customer expected to be stable compared to the prior year [7] Market Positioning - Tecan is well-positioned to benefit from robust underlying megatrends driving increased demand for healthcare solutions [8] - The company generated sales of CHF 934 million (USD 1,062 million; EUR 984 million) in 2024, with a global presence in over 70 countries [9]

Thermo Fisher Scientific (NYSE:TMO) is a global leader in serving science, providing innovative solutions for healthcare, life sciences, and industrial applications. The company is known for its comprehensive range of products and services, including laboratory equipment, analytical instruments, and specialty diagnostics. Thermo Fisher competes with other major players in the industry, such as Agilent Technologies and Danaher Corporation. Thermo Fisher recently introduced a new laboratory-developed test, th ...

MCLEAN, Va., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company committed to accelerating better health outcomes for its clients and the populations they serve, today announced that its Chief Health and Informatics Officer, Ryan Bosch, MD, has been named a 2025 Innovator in Health Care by the Washington Business Journal. The annual award recognizes Greater Washington’s top clinical and business leaders who are solving healthcare’s biggest challenges thr ...

Group 1 - The US is considered the best country for innovation in life sciences, with a strong belief in its capacity for research and development [1][2] - The country possesses essential elements for innovation, including universities, research institutions, talent attraction, capital markets, and capable companies [2] - There is an optimistic outlook for the life science industry, with a belief that it will continue to lead in healthcare innovation despite historical ups and downs [3]

Company Overview - Acentra Health is a technology and health solutions company focused on improving outcomes for government and commercial healthcare clients [1][5] - The company partners with 45 state agencies and 15 federal clients to enhance health outcomes and generate cost savings through advanced health IT and integrated health solutions [4] Leadership Recognition - CEO Todd Stottlemyer has been named to the 2025-26 Virginia 500 Power List, marking his fourth consecutive nomination, which recognizes top leaders in various sectors [1][2] - Stottlemyer's leadership has contributed to Acentra Health's growth and expansion, including multiple acquisitions since he joined the company in 2018 [2][3] Community Engagement - Stottlemyer is actively involved in civic leadership, serving on boards and councils that promote education and economic opportunity as pathways to better health outcomes [3] - Acentra Health has been a trusted partner to the Virginia Department of Medical Assistance Services since 2007, supporting two million residents under the Cardinal Care Medicaid program [4]

Wearable Telemetry Monitor 5500 September 4, 2025 Empowering clinical teams to respond to surges, track usage and ease workflows with user-friendly touchscreen technology for telemetry patients on the move Cambridge, Massachusetts – Philips, a global leader in health technology, today announced the introduction of an innovative telemetry platform designed to help address critical challenges in healthcare – including staff shortages and alarm management. A key component of the solution is the next-gener ...

Core Insights - HealthLynked Corp. has launched a newly designed Enterprise Healthcare Solutions Website and enhanced its consumer-facing provider directory, positioning itself as a key technology partner in the healthcare sector [1][2]. Group 1: New Website Launch - The new website serves as a dedicated platform for HealthLynked's commercial partners, showcasing tailored solutions for various stakeholders in the healthcare ecosystem [2]. - Dr. Michael Dent, CEO of HealthLynked, emphasized that the website reflects the company's expanding role and commitment to scalable solutions that improve healthcare outcomes and reduce costs [2][4]. Group 2: Enhanced Provider Directory - Major upgrades to the national provider directory have been implemented to enhance user experience, providing patients with more flexibility and transparency in selecting providers [3][6]. - The improvements aim to empower patients with smarter tools to manage their healthcare needs effectively [3][4]. Group 3: Strategic Vision and Commitment - The combination of the new website and upgraded provider directory demonstrates HealthLynked's commitment to innovation and strengthening strategic relationships within the healthcare landscape [4]. - The company continues to invest in technology that supports personalized patient care and enterprise-scale efficiency [4][5]. Group 4: Company Overview - HealthLynked Corp. is transforming healthcare through a cloud-based platform that connects patients and providers, offering secure medical record management, AI-driven insights, and a robust provider directory [5]. - The company provides various services tailored to insurance carriers, pharmaceutical companies, advertising firms, ACOs, healthcare networks, and large employers, focusing on improving access, cost savings, and coordinated care [5].

Core Insights - Acentra Health has been recognized as the 43rd largest private company by revenue in the Washington, D.C. region according to the Washington Business Journal's 2025 list [1] - The company has shown significant growth, climbing 23 spots over the last four years, indicating sustained revenue growth and increased market share [2] Company Performance - Acentra Health's growth is attributed to strategic investments in technology and workforce, enhancing its service delivery and operational efficiency [2][4] - The company serves clients across all 50 states, partnering with 47 state Medicaid agencies and 25 federal agencies, impacting over 140 million beneficiaries [4] Leadership Statements - The CEO, Todd Stottlemyer, emphasized the company's commitment to innovation and its role as a vital partner in health solutions, combining technology, clinical insight, and policy fluency [3] - Meghan Harris, President & COO, highlighted the trust placed in Acentra Health by clients to address complex healthcare challenges, focusing on improving health outcomes for priority populations [4] Recognition and Awards - Acentra Health has received multiple accolades, including the Corporate Growth Award from the Association for Corporate Growth National Capital Chapter and a spot on the Fastest Growing Companies list by the Washington Business Journal in 2024 [5] Company Overview - Acentra Health integrates public sector knowledge, clinical expertise, and technological innovation to enhance healthcare experiences for various partners [6] - The company is backed by Carlyle, a global investment firm, which supports its mission to modernize healthcare solutions [6]

Group 1 - Natalie Davis has been appointed as the new Chairman of the Board of Ramsay Générale de Santé, succeeding Craig McNally who held the position since 2017 [1][2] - Craig McNally is recognized for his eight years of commitment, particularly during the health crisis of 2020-2021, and for leading the Group to become a Mission Company in 2023 [2] - Natalie Davis brings extensive experience in service and customer relations, having previously worked at McKinsey & Company and Woolworths Group, and is expected to support the Group's objectives in Europe [2][4] Group 2 - Ramsay Santé is the European leader in private hospitalization and primary care, employing 38,000 staff and serving 12 million patients across 465 establishments in five countries: France, Sweden, Norway, Denmark, and Italy [5] - The Group is committed to improving health through innovation and participates in public health service missions, ensuring comprehensive healthcare pathways from prevention to follow-up [6] - Ramsay Santé invests over €200 million annually in innovation to enhance care pathways and strengthen healthcare access for all [7]

Core Insights - Prenetics Global Limited announced a partnership between its premium supplements brand IM8 and world No. 1 tennis player Aryna Sabalenka, who becomes the brand's global ambassador and shareholder [1][6][12] - This partnership is significant as it marks the first endorsement of a supplement brand by Sabalenka, who has reported substantial benefits from using IM8's Daily Ultimate Essentials [3][4][5] Company Overview - Prenetics is a leading consumer health sciences company listed on NASDAQ under the ticker PRE, focusing on advancing consumer health through various initiatives, including IM8 [10] - IM8, co-founded by David Beckham, has rapidly grown to generate over US$50 million in Annual Recurring Revenue within just six months of its launch [6][8] - IM8 has built a loyal customer base of over 60,000 users, delivering more than 5 million servings of its products [6][8] Product Details - IM8's flagship product, Daily Ultimate Essentials, is designed to replace 16 different supplements with a single, NSF Certified for Sport® powder supplement [11] - The product is non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors, or sweeteners [11] Market Context - The partnership comes at a time when supplement safety and quality are critical issues in professional sports, with IM8's NSF Certified for Sport® designation ensuring rigorous testing for prohibited substances [7] - IM8's revenue growth trajectory exceeds typical benchmarks for successful supplement launches by 500%, indicating strong market demand and acceptance [8]